Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. [electronic resource]
Producer: 20070404Description: 2320-4 p. digitalISSN:- 0931-0509
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20 -- immunology
- B-Lymphocyte Subsets -- drug effects
- Capillaries -- chemistry
- Complement C4b -- analysis
- Contraindications
- Cryoglobulinemia -- drug therapy
- Fatty Liver -- complications
- Female
- Follow-Up Studies
- Glomerulonephritis, Membranoproliferative -- drug therapy
- Graft Survival
- HLA Antigens -- immunology
- Hepatitis C, Chronic -- complications
- Humans
- Immunosuppressive Agents -- therapeutic use
- Interferon-alpha
- Kidney Transplantation
- Lymphocyte Count
- Middle Aged
- Peptide Fragments -- analysis
- Postoperative Complications -- drug therapy
- Recurrence
- Renal Dialysis
- Reoperation
- Rituximab
- Transplantation, Homologous
- Viral Load
- Viremia -- complications
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.